Cite
MLA Citation
Ilaria Alborelli et al.. “Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer.” Journal of pathology, vol. 250, no. 1, 2020, pp. 19–29. http://access.bl.uk/ark:/81055/vdc_100154584172.0x00005a